Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm

Marie-Paule Guillaume; Héloïse Reumaux; François Dubos

doi:10.1017/S1047951117002864

Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm

Cardiol Young. 2018 May;28(5):739-742. doi: 10.1017/S1047951117002864. Epub 2018 Feb 19.

Authors

Marie-Paule Guillaume¹, Héloïse Reumaux², François Dubos³

Affiliations

¹ 1Pediatric Cardiology,CHU Lille and University of Lille,Lille,France.
² 2Pediatric Rheumatology Unit,CHU Lille and University of Lille,Lille,France.
³ 3Pediatric Emergency unit and Infectious Diseases,CHU Lille and University of Lille,Lille,France.

PMID: 29455693
DOI: 10.1017/S1047951117002864

Abstract

Kawasaki disease is an acute self-limited vasculitis of unknown aetiology. The prognosis depends mainly on coronary damage. There is no consensus regarding optimal adjunctive therapeutics for refractory forms to treatment by intravenous immunoglobulins and corticosteroids. We report the case of an 18-month-old infant with refractory Kawasaki disease complicated by diffuse aneurysms of coronary arteries and successfully treated by anakinra with partial regression of coronary aneurysms.

Keywords: Refractory Kawasaki disease; anakinra; children; coronary aneurysm.

Publication types

Case Reports

MeSH terms

Antirheumatic Agents / administration & dosage
Coronary Aneurysm / diagnosis
Coronary Aneurysm / drug therapy*
Coronary Aneurysm / etiology
Coronary Angiography
Coronary Vessels / diagnostic imaging
Coronary Vessels / drug effects*
Dose-Response Relationship, Drug
Follow-Up Studies
Humans
Infant
Injections, Subcutaneous
Interleukin 1 Receptor Antagonist Protein / administration & dosage*
Male
Mucocutaneous Lymph Node Syndrome / complications*
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antirheumatic Agents
Interleukin 1 Receptor Antagonist Protein